Evidence map›Paper›PMID 33547331›Full record

Trial reportScientific reports2021

Variable selection methods for predicting clinical outcomes following allogeneic hematopoietic cell transplantation.

Chloé Pasin, Ryan H Moy, Ran Reshef, Andrew J Yates

Abstract readClinical Trial, Phase IClinical Trial, Phase II
In one paragraph

Trial report in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Chloé PasinDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, 10032, USA.
Ryan H MoyDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Ran ReshefColumbia Center for Translational Immunology and Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, NY, 10032, USA.
Andrew J YatesDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, 10032, USA. andrew.yates@columbia.edu.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3M
Modeling the development, structure and regulation of T cell memoryR01AI093870 · NIAID · UNIVERSITY OF GLASGOW · PI YATES, ANDREW · 2011 to 2025
$5.9M
Effector T-cell trafficking in graft-versus-host diseaseR01HL143424 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI RESHEF, RAN · 2019 to 2023
$2.0M
Lymphocyte trafficking blockade in allogeneic stem-cell transplantationK23CA178202 · NCI · UNIVERSITY OF PENNSYLVANIA · PI RESHEF, RAN · 2013 to 2015
$520k
NCI NIH HHS K23 CA178202NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA013696NHLBI NIH HHS R01 HL143424NIAID NIH HHS R01 AI093870
6 · The paper itself

Abstract

Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative procedure for a large number of diseases. However, the greatest barriers to the success of allo-HCT are relapse and graft-versus-host-disease (GVHD). Many studies have examined the reconstitution of the immune system after allo-HCT and searched for factors associated with clinical outcome. Serum biomarkers have also been studied to predict the incidence and prognosis of GVHD. However, the use of multiparametric immunophenotyping has been less extensively explored: studies usually focus on preselected and predefined cell phenotypes and so do not fully exploit the richness of flow cytometry data. Here we aimed to identify cell phenotypes present 30 days after allo-HCT that are associated with clinical outcomes in 37 patients participating in a trial relating to the prevention of GVHD, derived from 82 flow cytometry markers and 13 clinical variables. To do this we applied variable selection methods in a competing risks modeling framework, and identified specific subsets of T, B, and NK cells associated with relapse. Our study demonstrates the value of variable selection methods for mining rich, high dimensional clinical data and identifying potentially unexplored cell subpopulations of interest.

Indexed as

Hematopoietic Stem Cell TransplantationAdultB-LymphocytesFemaleGraft vs Host DiseaseHumansKiller Cells, NaturalMaleMiddle AgedPrognosisT-LymphocytesTransplantation, HomologousTreatment Outcome

Identifiers

PMID33547331
PMCPMC7865009

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.